Study Stopped
We recruited and completed all 3 interventions in 10 participants for bread and 10 for tortilla, but stopped at 8 participants (instead of 10) for arepa and two of these participants only completed 2 out of 3 interventions because funding end.
The Effect of the Inclusion of Soybean Flour on Glycemic Responses
1 other identifier
interventional
17
1 country
1
Brief Summary
Foods that release glucose rapidly, leading to spikes in blood sugar and insulin (known as high glycemic index foods), generate lower satiety responses than foods with low glycemic index. High glycemic index foods are also linked to an increased risk of developing diabetes. The partial replacement of carbohydrates in rich staple foods with soy flour has the potential to reduce glycemic response and improve satiety. In many regions of Latin America, as well as in the Middle East and North Africa (MENA) regions, bread is the staple source of calories, but it is a relatively poor source of balanced nutrition. Bread enriched with soy flour could provide higher dietary protein while moderating blood glucose (and insulin) spikes, which can help reduce insulin resistance and metabolic diseases. The results of this study could provide government and private human nutritionists with the evidence they need to formulate soy flour into bread, corn tortillas, and arepas for schools and homes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 20, 2024
CompletedFirst Posted
Study publicly available on registry
February 28, 2024
CompletedStudy Start
First participant enrolled
March 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 18, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2025
CompletedAugust 6, 2025
July 1, 2025
1.3 years
February 20, 2024
July 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Plasma glucose
Concentrations of glucose in plasma before and at different times post-prandially
-30 minutes to 120 min post-prandially
Plasma insulin
Concentrations of insulin in plasma before and at different times post-prandially
-30 minutes to 120 min post-prandially
Secondary Outcomes (1)
Hunger-Satiety
Before and after (10-180 min) they consume the different food products (bread, arepa, tortillas)
Study Arms (3)
Bread
EXPERIMENTALBread will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
Tortilla
EXPERIMENTALBread will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
Arepa
EXPERIMENTALArepa will be prepared with 100 % of wheat flour and with some replacements by different % of soy flour (at three concentrations)
Interventions
The intervention consist in replacing a fraction of wheat flour by soyflour
Eligibility Criteria
You may qualify if:
- Male and female between 21-45 years of age
- All races/ethnicities
- Body mass Index (BMI) \> 25 kg/m2 and \<40 kg/m2 (i.e., overweight and obesity, excluding severe obesity)
- Fat %: \> 30% for female or \> 20% for male
You may not qualify if:
- Currently smokes or quit smoking nicotine cigarettes, vapes or E-cigarettes for less than 6 months ago
- Pregnant, breastfeeding, menopausal
- Hemoglobin: \<11g/dl for female and \<13g/dl for male
- Blood donation in the past 8 weeks
- Gluten intolerance (Gluten allergy, wheat allergy, celiac disease), Soy intolerance or allergy
- Presence of malabsorption syndrome
- History of bariatric surgery
- Presence of inflammatory intestinal disease, liver, or kidney disease
- Diabetes (fasting glucose level \>126mg/dl or plasma glucose level 2h after glucose challenge \>200 mg/dl) or taking medicines to treat diabetes
- Polycystic ovary syndrome (pcos)
- Untreated hypertension
- Taking any medication that might affect glucose metabolism or the results of our study
- History of cancer \<5 years ago
- Abnormalities in the metabolic panel test (e.g., liver enzymes \>2 times the upper limit).
- Seizures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Illinois at Urbana Champaign
Champaign, Illinois, 61820, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marta Y Pepino de Gruev, PhD
University of Illinois at Urbana-Champaign
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- Participants will be given the food product without information on whether it is prepared 100% with wheat flour or with different soy flour %.
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 20, 2024
First Posted
February 28, 2024
Study Start
March 11, 2024
Primary Completion
June 18, 2025
Study Completion
June 20, 2025
Last Updated
August 6, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share